Aptose Biosciences Inc. (APS) Director William Glenn Rice Buys 10,000 Shares of Stock

Share on StockTwits

Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO) Director William Glenn Rice acquired 10,000 shares of Aptose Biosciences stock in a transaction that occurred on Thursday, April 18th. The stock was acquired at an average cost of C$2.44 per share, with a total value of C$24,429.24. Following the completion of the purchase, the director now owns 153,014 shares in the company, valued at approximately C$373,801.57.

William Glenn Rice also recently made the following trade(s):

  • On Thursday, March 14th, William Glenn Rice acquired 10,000 shares of Aptose Biosciences stock. The stock was acquired at an average cost of C$2.51 per share, with a total value of C$25,070.76.

Shares of APS stock opened at C$2.55 on Tuesday. Aptose Biosciences Inc. has a fifty-two week low of C$2.08 and a fifty-two week high of C$5.97. The stock has a market capitalization of $101.67 million and a price-to-earnings ratio of -2.95.

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) last issued its earnings results on Tuesday, March 12th. The biotechnology company reported C($0.22) earnings per share for the quarter, missing the consensus estimate of C($0.21) by C($0.01). Sell-side analysts anticipate that Aptose Biosciences Inc. will post -0.8399999904 earnings per share for the current year.

Separately, Royal Bank of Canada reissued an “outperform” rating and issued a C$6.00 price objective on shares of Aptose Biosciences in a research note on Friday, March 1st.

ILLEGAL ACTIVITY NOTICE: This report was posted by Highlight Press and is the sole property of of Highlight Press. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://highlightpress.com/2019/04/23/aptose-biosciences-inc-aps-director-william-glenn-rice-buys-10000-shares-of-stock.html.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Recommended Story: How to interpret a stock’s beta number

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.